{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:42:58Z","timestamp":1792798978510,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR-20-20744"],"award-info":[{"award-number":["ESR-20-20744"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Trans-Tasman Radiation Oncology Group","id":[{"id":"https:\/\/ror.org\/02cyrpr98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,11]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trans Tasman Radiation Oncology Group 20.01 CHEST-RT (Chemotherapy and Immunotherapy in Extensive Stage Small cell with Thoracic Radiotherapy) is a single-arm, open-label, prospective, multicentre phase II trial study that aims to establish the safety, feasibility and describe the efficacy of incorporating thoracic radiotherapy (TRT) (concurrent or sequential) to chemotherapy and immunotherapy in patients with extensive-stage small-cell lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single arm of up to 30 evaluable participants given TRT concurrent or sequentially with chemoimmunotherapy will be enrolled. Participants should commence radiotherapy with cycle 3 or cycle 4 of chemotherapy. Those not suitable for concurrent radiotherapy due to large tumour volumes may receive sequential radiotherapy. Accounting for a 15% non-evaluable rate, up to 35 participants will be enrolled. An independent data and safety monitoring committee will review the data and assess safety and feasibility. Progression to a phase III trial would be considered feasible if \u226420% of participants experienced \u2265grade 3 oesophageal toxicity and \u226410% experienced \u2265grade 3 pneumonitis. This approach would be considered feasible if there is \u226420% treatment discontinuation of systemic therapy secondary to radiation toxicities and \u226575% of participants have tumour volumes that can be safely treated to a dose of 30 Gy in 10 fractions. The primary outcome of the trial is safety and feasibility, and survival and responses will be assessed as secondary endpoints. A predefined subgroup analysis of toxicity will be performed on group 1 (concurrent TRT) versus group 2 participants (consolidation TRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study was approved by the Peter MacCallum Human Research Ethics Committee (HREC\/73189\/PMCC-2021). The protocol, technical and clinical data will be disseminated by conference presentations and publications. Any modifications to the protocol will be formally documented by administrative letters and will be submitted to the approving HREC for review and approval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      Australian New Zealand Clinical Trials Registry (ACTRN12621000586819) and ClinicalTrials.gov identifier (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05796089\">NCT05796089<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-101571","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T21:30:44Z","timestamp":1751923844000},"page":"e101571","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial \u2013 protocol for a phase II study"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05796089","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05796089","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-2489","authenticated-orcid":false,"given":"Sagun","family":"Parakh","sequence":"first","affiliation":[{"name":"Olivia Newton-John Cancer Centre at Austin Health, Heidelberg, Victoria, Australia"},{"name":"Medical Oncology, Austin Hospital, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Gee","sequence":"additional","affiliation":[{"name":"Radiation Oncology Network, Western Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"University of Sydney, Sydney, New South Wales, Australia"},{"name":"Children\u2019s Medical Research Institute, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Lim","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Austin Hospital, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8075-6219","authenticated-orcid":false,"given":"Shalini","family":"Vinod","sequence":"additional","affiliation":[{"name":"Cancer Therapy Centre, Liverpool Hospital, Liverpool, New South Wales, Australia"},{"name":"University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Trans Tasman Radiation Oncology Group, Waratah, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Rooney","sequence":"additional","affiliation":[{"name":"Trans Tasman Radiation Oncology Group, Waratah, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Trans Tasman Radiation Oncology Group, Waratah, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Harden","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Moore","sequence":"additional","affiliation":[{"name":"Medical Oncology, St Vincent\u2019s Hospital (Melbourne) Limited, Fitzroy, Victoria, Australia"},{"name":"Department of Medicine, University of Melbourne VCCC, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Lehman","sequence":"additional","affiliation":[{"name":"The University of Queensland, Saint Lucia, Queensland, Australia"},{"name":"Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bettington","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Royal Brisbane and Women\u2019s Hospital, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Moodie","sequence":"additional","affiliation":[{"name":"Westmead Hospital, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Barber","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Blacktown Hospital, Blacktown, New South Wales, Australia"},{"name":"Institute of Medical Physics, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Schmidt","sequence":"additional","affiliation":[{"name":"St George Cancer Care Centre, Kogarah, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Dizon","sequence":"additional","affiliation":[{"name":"Data Sciences, Hunter Medical Research Institute, The University of Newcastle, New Lambton Heights, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Leigh","sequence":"additional","affiliation":[{"name":"Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Oldmeadow","sequence":"additional","affiliation":[{"name":"Hunter Medical Research Institute, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Olivia Newton-John Cancer and Wellness Centre, Austin Health and Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hau","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Blacktown Hospital, Blacktown, New South Wales, Australia"},{"name":"Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Centre for Cancer Research, Westmead Institute of Medical Research, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2025121514241442000_15.7.e101571.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.002"},{"key":"2025121514241442000_15.7.e101571.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01881"},{"key":"2025121514241442000_15.7.e101571.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"2025121514241442000_15.7.e101571.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.87"},{"key":"2025121514241442000_15.7.e101571.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2025121514241442000_15.7.e101571.6","doi-asserted-by":"crossref","first-page":"107924","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"2025121514241442000_15.7.e101571.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"2025121514241442000_15.7.e101571.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464"},{"key":"2025121514241442000_15.7.e101571.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8"},{"key":"2025121514241442000_15.7.e101571.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2023.09.027","article-title":"OA01.06 First-Line Chemotherapy With or Without Tislelizumab for Extensive-Stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study","volume":"18","author":"Cheng","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2025121514241442000_15.7.e101571.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071780"},{"key":"2025121514241442000_15.7.e101571.12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","article-title":"Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937","volume":"12","author":"Gore","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2025121514241442000_15.7.e101571.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61085-0"},{"key":"2025121514241442000_15.7.e101571.14","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.1999.17.7.2092","article-title":"Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study","volume":"17","author":"Jeremic","year":"1999","journal-title":"J Clin Oncol"},{"key":"2025121514241442000_15.7.e101571.15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3857\/roj.2019.00192","article-title":"Higher thoracic radiation dose is beneficial in patients with extensive small cell lung cancer","volume":"37","author":"Yoon","year":"2019","journal-title":"Radiat Oncol J"},{"key":"2025121514241442000_15.7.e101571.16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cllc.2015.09.007","article-title":"Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis","volume":"17","author":"Palma","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"2025121514241442000_15.7.e101571.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"2025121514241442000_15.7.e101571.18","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"2025121514241442000_15.7.e101571.19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1719"},{"key":"2025121514241442000_15.7.e101571.20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2012.00088","article-title":"The convergence of radiation and immunogenic cell death signaling pathways","volume":"2","author":"Golden","year":"2012","journal-title":"Front Oncol"},{"key":"2025121514241442000_15.7.e101571.21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33083"},{"key":"2025121514241442000_15.7.e101571.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00630-6"},{"key":"2025121514241442000_15.7.e101571.23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025121514241442000_15.7.e101571.24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2022.10.006","article-title":"Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial","volume":"174","author":"Liu","year":"2022","journal-title":"Lung Cancer (Auckl)"},{"key":"2025121514241442000_15.7.e101571.25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025121514241442000_15.7.e101571.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"2025121514241442000_15.7.e101571.27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025121514241442000_15.7.e101571.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2025121514241442000_15.7.e101571.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1065510","article-title":"Safety and efficacy of radiotherapy\/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"2025121514241442000_15.7.e101571.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873"},{"key":"2025121514241442000_15.7.e101571.31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.08.013","article-title":"Concurrent Chemoradiation \u00b1 Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology\/Alliance LU005","volume":"120","author":"Higgins","year":"2024","journal-title":"International Journal of Radiation Oncology, Biology, Physics"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-101571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:24:23Z","timestamp":1765837463000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-101571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,7]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2025-101571"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-101571","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}